You might also like
Boston Scientific Corporation is a global company that develops, manufactures, and markets medical devices for various interventional medical specialties . The company operates through two main segments: MedSurg and Cardiovascular, offering a diverse range of products . Boston Scientific's product portfolio includes devices for gastrointestinal, pulmonary, urological, neurological, and cardiovascular conditions, driven by strategic growth and expansion into emerging markets .
- Cardiology - Develops and markets medical devices for heart-related conditions, contributing significantly to the company's overall sales.
- Peripheral Interventions - Provides devices for treating peripheral vascular diseases, enhancing the company's cardiovascular offerings.
- Endoscopy - Focuses on devices for gastrointestinal and pulmonary conditions, supporting minimally invasive procedures.
- Urology - Offers medical devices for urological conditions, addressing a wide range of patient needs.
- Neuromodulation - Addresses neurological movement disorders and chronic pain through innovative device solutions.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Michael F. Mahoney ExecutiveBoard | President, CEO, and Chairman of the Board | Board Member at CVS Health Corporation; Boys & Girls Club of Boston; Boston College CEO Club; American Heart Association CEO Roundtable | Joined BSX in 2011 as President, became CEO in 2012, and Chairman in 2016. Recognized for leadership in medical devices and healthcare. | View Report → |
Arthur C. Butcher Executive | Executive Vice President and Group President, MedSurg and Asia Pacific | Board Member at Acotec Scientific | Joined BSX in 1997, leads MedSurg and Asia Pacific since 2022. Focuses on endoscopy and urology. | |
Daniel J. Brennan Executive | Executive Vice President and CFO | Board Member at Waters Corporation | Joined BSX in 1996, became CFO in 2014. Oversees finance, audit, and investor relations. Co-Chair of Global Council for Inclusion. | |
Eric Thépaut Executive | Executive Vice President and President, EMEA | N/A | Joined BSX in 1996, leads EMEA operations since 2020. Extensive experience in finance and marketing. | |
Jeffrey B. Mirviss Executive | Executive Vice President and President, Peripheral Interventions | N/A | Joined BSX in 1997, leads Peripheral Interventions since 2020. Focuses on arterial and venous system treatments. | |
John Bradley Sorenson Executive | Executive Vice President, Global Operations | N/A | Joined BSX in 1997, oversees global operations since 2022. Focuses on supply chain and regulatory affairs. | |
Vance R. Brown Executive | Senior Vice President, General Counsel, and Corporate Secretary | N/A | Joined BSX in 2010, General Counsel since 2021. Oversees legal and compliance functions. | |
Wendy Carruthers Executive | Executive Vice President, Human Resources | Board Member at Envista Holdings Corporation; Boston Scientific Foundation | Joined BSX in 2004, leads HR since 2022. Focuses on diversity and inclusion. | |
David Habiger Board | Director | President and CEO of J.D. Power; Director on Chicago Federal Reserve Board and Rush University Medical Center | Director since 2024. Extensive experience in technology and business leadership. | |
David S. Wichmann Board | Director | Board Member at Privia Health Group, Inc. | Director since 2021. Former CEO of UnitedHealth Group, extensive experience in healthcare management. | |
Dr. Cheryl Pegus Board | Director | Board Member at American Heart Association; Co-founder of A New Beat | Director since 2024. Former EVP at Walmart, extensive experience in healthcare innovation and equity. | |
Edward J. Ludwig Board | Lead Independent Director | Board Member at CVS Health Corporation | Director since 2014, Lead Independent Director since 2016. Former CEO of Becton, Dickinson and Company. | |
Ellen M. Zane Board | Director | Board Member at Haemonetics Corporation and Synchrony Financial | Director since 2016. Former CEO of Tufts Medical Center, extensive experience in healthcare leadership. | |
Jessica L. Mega Board | Director | Director at Danaher Corporation; Board of Advisors at Duke-Margolis Center for Health Policy and Research!America | Director since 2023. Co-founder of Verily Life Sciences, extensive experience in clinical trials and genomics. | |
John E. Sununu Board | Director | Director at BlueRiver Acquisition Corp.; Council Member at Lloyds of London | Director since 2009. Former U.S. Senator and Representative, extensive experience in public policy and governance. | |
Susan E. Morano Board | Director | N/A | Director since 2023. Former VP at Johnson & Johnson MedTech, extensive experience in business development. | |
Yoshiaki Fujimori Board | Independent Director | Senior Executive Advisor of Japan to CVC Capital Partners; Board Member at Oracle Corporation Japan and Takeda Pharmaceutical Company Limited | Director since 2016. Extensive experience in international business and technology. |
-
Can you provide more details on the unanticipated observations that led to the temporary pause of the AVANT GUARD trial for FARAPULSE in drug-naïve persistent AF patients, and how might this impact your timeline for resuming enrollment and obtaining label expansion?
-
With new pulse field ablation (PFA) catheters entering the market, what specific strategies are you implementing to ensure that existing FARAPULSE customers remain loyal and to attract new users, especially given the competitive landscape?
-
In the U.S., your core Cardiac Rhythm Management (CRM) growth was below market. What factors contributed to this underperformance, and what actions are you taking to improve your position in this segment?
-
Regarding the upcoming presentation of the ACURATE neo2 trial data at TCT, if the results are not as positive as anticipated, how will this affect your TAVR strategy in the U.S., and what contingency plans do you have in place?
-
Given your expectation that pulse field ablation adoption may exceed the previously communicated range of 40% to 60% of global AF ablations by 2026, do you foresee any potential supply constraints, and how are you ensuring your manufacturing capacity can meet this increased demand?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The company encounters significant competition from this entity across its product lines and markets, as it is one of the primary competitors in the medical device industry. | |
This entity is identified as a primary competitor in the medical device markets where the company operates, competing across various product lines and market segments. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Cortex, Inc. | 2025 | Boston Scientific acquired Cortex, Inc. for an upfront cash payment of $248 million with up to $50 million in contingent payments, integrating Cortex’s diagnostic mapping solution for atrial fibrillation into its Cardiology division. |
Bolt Medical, Inc. | 2025 | Boston Scientific’s acquisition of Bolt Medical, Inc. involves an upfront payment of about $443 million for the remaining 74% stake (in addition to its existing 26% equity) plus $221 million contingent on regulatory milestones; the deal expands its cardiovascular portfolio with an advanced intravascular lithotripsy platform integrated into the Cardiology and Peripheral Interventions divisions. |
Axonics, Inc. | 2024 | The acquisition of Axonics, Inc. was completed for $71 per share, totaling an equity value of $3.7 billion funded by cash and new debt; it expands the Urology division by adding sacral neuromodulation systems and related urinary continence devices. |
Silk Road Medical, Inc. | 2024 | Boston Scientific acquired Silk Road Medical, Inc. for $27.50 per share (approximately $1.18 billion enterprise value), funding the deal with cash on hand and potential commercial paper, and integrating its transcarotid artery revascularization platform into the Peripheral Interventions division to enhance stroke prevention offerings. |
Intera Oncology, Inc. | 2024 | A definitive agreement was announced to acquire Intera Oncology, Inc. (expected to complete in the first half of 2025), which brings the Intera 3000 Hepatic Artery Infusion Pump and floxuridine into Boston Scientific’s interventional oncology portfolio for treating liver-dominant metastases; financial terms remain undisclosed. |
Apollo Endosurgery, Inc. | 2023 | Completed on April 4, 2023, this acquisition involved an upfront cash payment of $636 million; Apollo Endosurgery’s suite of endoluminal devices was integrated into the Endoscopy division, contributing positively to Q2 net sales growth. |
Acotec | 2023 | Completed on February 20, 2023, Boston Scientific acquired approximately 65% of Acotec for an upfront cash payment of about $519 million (net $381 million after cash on hand), strengthening its Peripheral Interventions portfolio in China with drug-coated balloons and related technologies. |
Baylis Medical Company Inc. | 2022 | Acquired on February 14, 2022, the deal involved an upfront cash payment of $1.75 billion (netting approximately $1.47 billion), integrating advanced transseptal access solutions into the Cardiology division to bolster electrophysiology and structural heart therapy products. |
M.I. Tech Co., Ltd. | 2022 | Boston Scientific acquired approximately 64% of M.I. Tech for KRW 291.2 billion (roughly $230 million), with the deal expected to close in the second half of 2022; it is aimed at complementing the Endoscopy portfolio by adding medical devices for endoscopic and urological procedures. |
Recent press releases and 8-K filings for BSX.
- Q1 2025 Performance: Boston Scientific delivered consolidated revenue of $4.663 billion with strong growth—22% operational and +20.9% reported—with adjusted EPS of $0.75 (up 34% YoY) .
- Margins Excellence: Achieved an adjusted operating margin of 28.9% and a gross margin of 71.5%, driven by a strong product mix and robust key product sales .
- Segment Highlights: Notable performance with the Cardiovascular segment up +26.2% and the MedSurg segment growing +11.7% YoY .
- Guidance & Tariff Impact: For FY 2025, guidance expects 15%-17% reported growth, 12%-14% organic growth, and adjusted EPS between $2.87 and $2.94 amid a $200M tariff headwind, with positive Q2 outlook .
- CFO Transition: Dan Brennan retires after nearly 30 years (retiring effective June 29, 2025, and serving as a senior advisor) with Jon Monson succeeding him effective June 30, 2025 .
- Strategic Investments: The portfolio is set to be enhanced with acquisitions including Bolt Medical and the upcoming SoniVie .
- Net sales of $4.663 billion in Q1 2025, reflecting a 20.9% reported growth over the prior year period.
- GAAP net income of $674 million (EPS of $0.45), up from $495 million (EPS of $0.33) in Q1 2024, indicating improved profitability.
- Demonstrated strong performance across key segments that underscores effective operational execution and product portfolio strength.
- Initiated pivotal clinical trials, reinforcing Boston Scientific’s strategic leadership.